Number of shares and voting rights of Innate Pharma as at May 5, 2017
Number of shares and voting rights of Innate Pharma as at april 4, 2017
Innate Pharma: 2016 reference document made available (in french)
Expansion of Phase I/II trial evaluating lirilumab in combination with Opdivo (nivolumab) in patients with advanced solid tumors
2016: Operational progress and robust financial position for further growth
Clinical and preclinical data on monalizumab to be presented at AACR annual meeting 2017
Number of shares and voting rights of Innate Pharma as at february 7, 2017
Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab as a single agent in elderly patients with acute myeloid leukemia
2014 Half-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb for continued exploration of lirilumab in combination with Opdivo
